Scott Delach
Overview
Explore the profile of Scott Delach including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
6
Citations
195
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Tiedt R, King F, Stamm C, Niederst M, Delach S, Zumstein-Mecker S, et al.
Cell Rep
. 2023 Mar;
42(4):112297.
PMID: 36961816
Anti-tumor efficacy of targeted therapies is variable across patients and cancer types. Even in patients with initial deep response, tumors are typically not eradicated and eventually relapse. To address these...
2.
Monaco K, Delach S, Yuan J, Mishina Y, Fordjour P, Labrot E, et al.
Clin Cancer Res
. 2020 Dec;
27(7):2061-2073.
PMID: 33355204
Purpose: Targeting RAF for antitumor therapy in RAS-mutant tumors holds promise. Herein, we describe in detail novel properties of the type II RAF inhibitor, LXH254. Experimental Design: LXH254 was profiled...
3.
Liu C, Lu H, Wang H, Loo A, Zhang X, Yang G, et al.
Clin Cancer Res
. 2020 Oct;
27(1):342-354.
PMID: 33046519
Purpose: SHP2 inhibitors offer an appealing and novel approach to inhibit receptor tyrosine kinase (RTK) signaling, which is the oncogenic driver in many tumors or is frequently feedback activated in...
4.
Kim S, Tiedt R, Loo A, Horn T, Delach S, Kovats S, et al.
Oncotarget
. 2020 Apr;
11(14):1289.
PMID: 32292577
[This corrects the article DOI: 10.18632/oncotarget.26215.].
5.
Kim S, Tiedt R, Loo A, Horn T, Delach S, Kovats S, et al.
Oncotarget
. 2018 Nov;
9(81):35226-35240.
PMID: 30443290
Inhibition of cyclin-dependent kinases 4 and 6 (CDK4/6) is associated with robust antitumor activity. Ribociclib (LEE011) is an orally bioavailable CDK4/6 inhibitor that is approved for the treatment of hormone...
6.
Hart L, Rader J, Raman P, Batra V, Russell M, Tsang M, et al.
Clin Cancer Res
. 2016 Oct;
23(7):1785-1796.
PMID: 27729458
Neuroblastoma is treated with aggressive multimodal therapy, yet more than 50% of patients experience relapse. We recently showed that relapsed neuroblastomas frequently harbor mutations leading to hyperactivated ERK signaling and...